Overview

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in advanced and metastatic solid tumor.
Phase:
Phase 1
Details
Lead Sponsor:
3D Medicines (Sichuan) Co., Ltd.
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins